Investors need to pay close attention to Catalent (CTLT) stock based on the movements in the options market lately.
Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The contract drug manufacturer was expected to file the report on Aug. 29. The company is awaiting the closing of the $16.5 billion takeover deal signed in February by Novo Holdings, the investment firm that has a controlling interest in Danish drugmaker Novo Nordisk. Catalent expects the deal to close towards the end of the year.